ARS Pharmaceuticals (NASDAQ: SPRY) reported strong financial results for its first full year of commercial sales of neffy, generating $72.2 million in net product revenue and a total revenue of $84.3 million. The company highlighted significant prescriber adoption, with over 22,500 healthcare providers now prescribing neffy, and a focus on high-volume practices, particularly allergists and pediatricians. Despite the challenges of operating in a refill-driven market, management is optimistic about growth as they expand their sales force and enhance marketing efforts.
The financial implications are noteworthy as ARS aims to maintain stable SG&A expenses while increasing its sales representatives from 106 to 150. The company’s gross-to-net retention is projected to improve as prior authorization requirements decline and coverage broadens, particularly with ongoing negotiations with major payers like CVS Caremark.
A key takeaway for market professionals is the potential for neffy’s prescription growth to accelerate in 2026, driven by increased provider engagement and a strategic focus on reducing administrative barriers, which could enhance overall market penetration.
Source: fool.com